Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04806594
Other study ID # ReGl/19/PAS-Acn/001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 25, 2020
Est. completion date July 1, 2021

Study information

Verified date January 2022
Source Relife S.r.l.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The scope of this open label clinical trial is to evaluate and confirm the performance of Papix acne scar in the prevention and improvement of acne scars in subject suffering for mild to moderate acne. The product will be applied for 8 consecutive weeks and 3 clinical follow up visits will be performed.


Description:

The scope of this open label clinical trial is to evaluate and confirm the performance of Papix acne scar in the prevention and improvement of acne scars in subject suffering for mild to moderate acne. The product will be applied for 8 consecutive weeks, 2 times per day into the face. The dermatologist will perform 3 clinical follow up visits to assess the efficacy and safety of the product.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date July 1, 2021
Est. primary completion date July 1, 2021
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: 1. Subject's or parents or guardian (depending on the age of the subject) written informed consent obtained prior to any study-related procedures; 2. Male or female subjects aged = 12 years of any race; 3. Subjects with any Fitzpatrick skin phototype; 4. Subjects with clinical diagnosis of mild to moderate acne vulgaris (IGA score 2 or 3) on the face; 5. Presence of acne scars (all types included), of grade mild or moderate according to SGA; 6. Subjects with cooperative attitude, able to comprehend the full nature and the purpose of the investigation, including possible risks and side effects, and able to comply with the requirements of the entire investigation (including ability to attend the planned visits according to the time limits), based on Investigator's judgement. Exclusion Criteria: 1. Pregnant women 2. Severe acne at inclusion or any acne requiring systemic treatment; 3. Presence of facial warts or fungal infections; 4. Active dermatitis on the face, rosacea, active herpes simplex; 5. Keloids presence in the area to be treated or keloids development during the treatment period; 6. History of radiation or skin tumors in the/close to the area to be treated in the past 5 years; 7. Laser ablative procedures within the last month; 8. Chemical peels within the last 6 months; 9. Use of topical treatments like antibiotics, corticosteroids, benzoyl peroxide, azelaic acid, hydroxy acids and other antinflammatory drugs within 2 weeks; 10. Use of topical retinoids within 4 weeks; 11. Use of systemic corticosteroids or antibiotics in the previous 30 days; 12. Use of systemic spironolactone/drospirenone or immunomodulators in the previous 3 months; 13. Use of oral retinoids or cyproterone acetate/chlormadinone acetate in the previous 6 months; 14. Use of scrub, alpha hydroxy acid (AHA), skin irritant products in the 2 days before study treatment start; 15. Subjects with any other clinically significant or unstable concurrent disease or skin condition or general condition that, in the Investigator's opinion, might interfere with the study evaluations; 16. Allergy, sensitivity or intolerance to the components of the investigational device formulations ingredients; 17. Concomitant or previous participation in other interventional clinical study in the past 3 months; 18. Subjects planning sun exposure or tanning booths or UV sources throughout the course of the study. In case of sun exposure this shall be limited and a protection cream (SPF 50+) shall be applied.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Papix acne scar
PapiX acne scar, class IIa medical device, gel for acne scar. to be applied 2 times per day during the 8 weeks of study duration

Locations

Country Name City State
Italy Ospedale San Martino Genova

Sponsors (1)

Lead Sponsor Collaborator
Relife S.r.l.

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other adverse event collection To evaluate the local and general tolerability of PAPIX ACNE SCAR. two weeks, 4 weeks and 8 weeks of treatment
Primary To evaluate and confirm the performance of PAPIX ACNE SCAR in the prevention and improvement of scars in subject suffering for mild to moderate acne, after 4 weeks of treatment Indicate the proportion of subjects with improved acne scars and marks respect to baseline and, at the same time, without any new facial acne scars after 4 weeks of treatment with the change in the qualitative Scar Global Assessment (SGA) questionnaire. four weeks of treatment
Secondary To evaluate the performance of PAPIX ACNE SCAR in the prevention and improvement of scars after 2 and 8 weeks of treatment. Indicate the proportion of subjects with improved acne scars and marks with respect to baseline and, at the same time, without any new facial acne scars after 2 and 8 weeks of treatment. The improvement of acne scars and marks will be assessed as the change in the qualitative Scar Global Assessment (SGA) questionnaire two weeks of treatment and 8 weeks of treatment
Secondary To evaluate the performance of PAPIX ACNE SCAR in the prevention of lesions after 2, 4 and 8 weeks of treatment Indicate the prevention of acne lesions after 2, 4 and 8 weeks of treatment. two weeks, 4 weeks and 8 weeks of treatment
Secondary evaluate acne severity To evaluate acne severity after 2, 4 and 8 weeks of treatment, through the Investigator Global Assessment. two weeks, 4 weeks and 8 weeks of treatment
Secondary skin roughness improvement To evaluate the improvement of the skin roughness after 2, 4 and 8 weeks of treatment.through the Investigator Global Assessment two weeks, 4 weeks and 8 weeks of treatment
Secondary skin texture improvement To evaluate the change in skin texture after 2, 4 and 8 weeks of treatment, through the Investigator Global Assessment two weeks, 4 weeks and 8 weeks of treatment
Secondary treatment compliance To evaluate the subject's adherence to treatment by the product accountability. 8 weeks
Secondary Subject and Investigator Global Evaluation of Performance To evaluate the subject's and Investigator's global evaluation of satisfaction with regards to the performance of PAPIX ACNE SCAR through a specific questionnaire. 8 weeks of treatment
Secondary Treatment acceptability To evaluate the subject's overall acceptability of the treatment through a specific questionnaire. 8 weeks of treatment
See also
  Status Clinical Trial Phase
Completed NCT05097157 - Study To Assess A Radiofrequency Microneedling Device For Dermatologic Conditions N/A
Completed NCT05131373 - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris Phase 1
Recruiting NCT03465150 - Creation of a Monocentric Cohort of Patients Treated for Acne at the Nantes University Hospital
Completed NCT02250859 - A Pharmacokinetic Study of Minocycline in Male and Female Volunteers Phase 1
Completed NCT01206348 - Combination Treatment for Moderate to Severe Acne Phase 4
Terminated NCT01193764 - Study Assessing the Effect of Chocolate Consumption in Subjects With A History of Acne Vulgaris N/A
Completed NCT00725439 - An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne Phase 2
Completed NCT05640388 - Assessment of a Cosmetic Product Effect on the Host/Microorganism Relationship in Acneic Subjects
Completed NCT04873089 - Efficacy Study of Cosmetic Product RV3278AET0943 Versus Non-treated Group in Adults With Oily and Acne Prone Skin
Recruiting NCT05941065 - Study of Skin Balancing Gel Cream Safety and Influence of Skin Microbiome on Acne Prone Skin N/A
Recruiting NCT06120452 - A Clinical Trial to Evaluate the Effectiveness of an Acne Serum in Improving Facial Acne and Post-Acne Pigmentation N/A
Completed NCT04300010 - Blue Light Therapy of C. Acnes Phase 4
Recruiting NCT06202274 - Clinical Study to Evaluate the Safety and Efficacy of Candela Technology N/A
Completed NCT04559022 - Pilot Study Investigating the Efficacy of Fat Grafting as a Treatment for Male and Female Facial Acne Scarring N/A
Terminated NCT02431494 - Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris N/A
Completed NCT05469880 - Efficacy and Tolerance of Formula 609613 37 in Acneic Patients N/A
Completed NCT02944461 - Efficacy and Safety of Aczone 7.5% Gel in the Treatment of Truncal Acne Vulgaris Phase 4
Completed NCT01951417 - Adapalene BPO Gel Pump, Moisturizer SPF 30 and Foam Wash in Patients With Mild to Moderate Acne Vulgaris Phase 4
Completed NCT01701024 - Clinical Study to Test the Efficacy and Safety of ACYC to Treat Moderate to Severe Acne Phase 3
Completed NCT01245946 - Photodynamic Therapy Compared to Adapalene 0.1% Gel Plus Doxycycline in the Treatment of Acne Vulgaris Phase 2